arcadia biosciences glp-1 receptor agonist weight management diabetes treatments agonism: a transformative approach for managing type-2 and obesity | Saudi Pharmaceutical Journal How GLP-1 Receptor Agonists Evolved
Description
These medications provide effective glycaemic control, significant weight reduction, and cardiovascular protection through complex signalling pathways affecting pancreatic, gastrointestinal, neural, and cardiovascular tissues
The GLP-1 receptor is expressed in a diverse range of organ systems including gastrointestinal (GI) tract, pancreas, heart, liver, and brain
The available doses of liraglutide are 0.6 mg, 1.2 mg, or 1.8 mg for type 2 diabetes, and 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg for obesity, respectively
It does not make heart disease worse, but it does not actively protect against it either
It does not suggest the same kind of gravitas that the Nobel prize carries
[DOI] [PMC free article] [PubMed] [Google Scholar] 128.Nogueiras R, et al
